CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 160 filers reported holding CRISPR THERAPEUTICS AG in Q4 2018. The put-call ratio across all filers is 1.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $43,337,000 | -27.8% | 518,146 | -36.5% | 0.01% | -30.8% |
| Q2 2020 | $59,997,000 | +99.6% | 816,395 | +15.2% | 0.01% | +62.5% |
| Q1 2020 | $30,066,000 | -29.4% | 708,952 | +1.4% | 0.01% | -11.1% |
| Q4 2019 | $42,593,000 | +6.0% | 699,336 | -28.6% | 0.01% | 0.0% |
| Q3 2019 | $40,165,000 | -33.2% | 979,892 | -23.3% | 0.01% | -30.8% |
| Q2 2019 | $60,151,000 | +15.8% | 1,277,089 | -12.2% | 0.01% | +8.3% |
| Q1 2019 | $51,959,000 | +116.1% | 1,454,630 | +72.9% | 0.01% | +100.0% |
| Q4 2018 | $24,040,000 | -29.8% | 841,438 | +8.9% | 0.01% | -14.3% |
| Q3 2018 | $34,260,000 | -42.4% | 772,473 | -23.6% | 0.01% | -46.2% |
| Q2 2018 | $59,430,000 | +41.4% | 1,011,415 | +10.0% | 0.01% | +30.0% |
| Q1 2018 | $42,031,000 | +158.3% | 919,514 | +23.0% | 0.01% | +150.0% |
| Q1 2017 | $16,272,000 | +8.4% | 747,450 | +0.4% | 0.00% | 0.0% |
| Q4 2016 | $15,007,000 | – | 744,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |